Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 18;13(8):e068616. doi: 10.1136/bmjopen-2022-068616

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Change in (A) MMD and (B) MSMD from baseline. The mean (SE) change from baseline in MMD and MSMD during the DBTP and OLTP is shown for the treatment groups. For the OLTP, data are shown for the total population. The dotted line indicates that patients in the placebo group during the DBTP received erenumab 70 mg during the OLTP starting at week 24. *The number of patients in the efficacy analysis set during the DBTP. Error bars represent SE. n=number of patients with observed data. DBTP, double-blind treatment period; MMD, monthly migraine days; MSMD, monthly acute migraine-specific medication treatment days; OLTP, open-label treatment period.